BNET Industries
Last Fiscal Year Sales:$17.5M
- Private
- US
Dow Jones Description
Abbott's rapidly growing molecular diagnostics business provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. The business includes instruments and reagents used to conduct sophisticated analysis of patient DNA and RNA. In 2002, Abbott formed an alliance with Celera Diagnostics focused on developing and marketing a broad menu of next-generation molecular diagnostics products for unmet medical and laboratory needs. Abbott offers innovative genomic tests for chromosome changes associated with congenital disorders and cancer, including the Vysis PathVysion HER-2 DNA Probe kit to identify women with metastatic breast cancer who could benefit from Herceptin therapy, and UroVysion , which detects genetic changes in bladder cells for use in monitoring bladder cancer recurrence and for use as an aid in the initial diagnosis of bladder cancer in patients with hematuria (blood in urine) suspected of having bladder cancer.
Number of Employees 400
Peer Companies
NAICS Code : 339111
News & Analysis
Filter by
vysis inc. - All News and Analysis
Abbott to shift 200 jobs to new Des Plaines location.(News)
- 2003-08-09
Byline: Amy McLaughlin Daily Herald Staff Writer Abbott Laboratories will consolidate its fast-growing $3 billion molecular diagnostics business in the former Sandoz Agro Inc. property in Des Plaines. Des Plaines city officials could hardly contain their excitement Friday when they announced...
Abbott Laboratories, Abbott Park, Ill., has agreed to purchase Vysis Inc.(Brief Article)
- 2002-01-01
Abbott Laboratories, Abbott Park, Ill., has agreed to purchase Vysis Inc. for $355 million. The acquisition is a move by Abbott to expand its offerings of diagnostic-testing equipment. Vysis makes genetic tests for cancer, prenatal disorders and other diseases. It sells diagnostic materials for...
Abbott buys Vysis
- 2001-10-31
Abbot Park and Downers Grove, IL 10//24/01--Abbott Laboratories will acquire Vysis, Inc. for approximately $355 million in cash. Vysis develops and markets clinical lab products for genetic disease evaluation and management. BP America's Amoco Technology, which owns approximately 65% of Vysis outstanding shares, will tender and not withdraw all of...
Abbott Bolsters Diagnostics Hold In Agreement to Purchase Vysis.(Abbott Laboratories acquires Vysis Inc.)(Brief Article)
- 2001-10-29
IN A MOVE TO get a leg up in the molecular diagnostics market, Abbott Laboratories has agreed to acquire genomics disease management company Vysis Inc. Abbott will pay $30.50 per share in a cash tender for all shares of Vysis in a transaction value ...
Abbott Laboratories to Buy Biotech Company in Downers Grove, Ill.
- 2001-10-25
By Bruce Japsen, Chicago Tribune Knight Ridder/Tribune Business News By Bruce Japsen, Chicago Tribune Knight Ridder/Tribune Business News
Local Focus.(Business)
- 2001-08-03
Vysis gains approval to sell cancer test DOWNERS GROVE - Downers Grove-based Vysis Inc. shares rose 11 percent Thursday after the maker of DNA-based tests won Food and Drug Administration approval to sell its UroVysion test for bladder cancer, Bloomberg News reported. Vysis shares...
Shares of Illinois-Based Biotech Firm Rise on FDA's Approval of Cancer Test.
- 2001-08-03
By Bruce Japsen, Chicago Tribune Knight Ridder/Tribune Business News By Bruce Japsen, Chicago Tribune Knight Ridder/Tribune Business News
Local firm's genetic test gets a workout in study.(Vysis Inc. breast cancer gene test)(Brief Article)
- 2001-01-08
Vysis Inc. of Downers Grove is going under the microscope-quite willingly. The maker of genetic tests was selected last month to provide a critical tool to an international research group that's tracking a telltale gene believed to be linked to breast cancer. ...
Vysis, Inc - Brief Article
- 2000-04-01
Vysis, Inc., a genomic disease management company, has obtained exclusive rights to Yale University's European FISH technology, chromosomal in situ suppression hybridization, and other related US and foreign patents and pending patent application.
Genetic testing's new possibilities Company takes the wait out of prenatal, cancer screening.(Business)
- 2000-02-22
As scientists move toward unraveling and mapping our DNA, Vysis Inc. may have the tools to quickly and accurately diagnose ailments from cancer to birth defects. One of the leading products from the Downers Grove-based company reduces the amount of time expectant parents must...
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Brown Shoe Co. Inc. Q3 2009 Earnings Call Transcript
on Nov 24, 2009about BWS
-
Daktronics Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Nov 24, 2009about DAKT
-
Haynes International Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
on Nov 24, 2009about HAYN
-
Valspar Corp. F4Q09 (Qtr End 30/10/09) Earnings Call Transcript
on Nov 23, 2009about VAL
-
Donaldson Company Inc. F1Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Nov 19, 2009about DCI
Glass Door
Manufacturing Industry Companies
| Company | Employer Rating |
| Alcoa |  |
| United Technologies | |
| BAE SYSTEMS (United Kingdom) | |
| Textron |  |
| Boeing | |
IndustryTop Rated
